The Great Alzheimer's Scam and The Proven Cures They've Buried for Billions. Decades of neglect in understanding the actual causes of dementia have transformed it into one of the most costly diseases in existence. By A Midwestern Doctor (10/05/25). Updated 12/15/25 with abridged version link.

• Full article: midwesterndoctor.com/p/…

• 🆕 Abridged version: midwesterndoctor.com/p/…

Alzheimer’s Disease (AD) and other dementias have caused untold emotional, physical, and financial trauma for billions. Obscene amounts of money have been spent on profit-driven research with few positive results.

A Midwestern Doctor (AMD) — in a characteristically long but important and thoroughly researched article — unravels truths about AD and dementia, related research and drug treatments, and even fraudulent studies. AMD offers forgotten solutions that have been hidden, censored, and ridiculed for decades.

If you know someone with dementia, please do share this article with that person’s caregiver (or with them, if they’re in early stages). Who wouldn’t want to use safe and effective alternative treatments for this devastating disease?

Contents

• The Amyloid Juggernaut

• Amyloid Scandals

• The Amyloid Industry

• Dale Bredesen’s Discovery

• What Causes Alzheimer’s Disease?

• Zeta Potential and Alzheimer’s

• Sleep and Dementia

• The Life of Cells

  • The Cell Danger Response

• DMSO and Dementia

• Treating Dementia

  • DMSO

  • Zeta Potential

  • Head Trauma

  • Other Therapies

  • Cell Danger Response Treatments

• Conclusion

Summary (Grok ai, edited; images from article)

The dominant amyloid hypothesis in Alzheimer's research employs fraudulent data that sustained billions in funding for ineffective drugs (with side effects such as brain bleeding), while ignoring affordable treatments targeting root causes (e.g., inflammation, toxins, impaired circulation, and cellular stress responses).

AMD discusses alternative models like Dale Bredesen's subtypes of Alzheimer's, zeta potential's role in fluid dynamics, sleep's importance, and therapies including DMSO. Evidence from studies and case reports showing cognitive improvements from these alternatives.

The Amyloid Hypothesis and Research Failures The amyloid hypothesis posits that Alzheimer's results from amyloid plaque buildup in the brain. Since 1906, plaques were linked to the disease; in 1984, amyloid beta was identified as their main component; in 1991, genetic mutations in amyloid precursor were tied to inherited forms.

Billions in funding, including NIH's $3.9 billion in 2024, focused on amyloid removal, but hundreds of trials failed.

Approved drugs such as Aduhelm slow progression minimally but cause brain bleeding and swelling in 21-41% of patients.

• Despite failures, amyloid research dominates, with $1.6 billion NIH funding in one year for amyloid-related projects.

• Critics label it the "amyloid mafia," sidelining alternatives including immune dysfunction or inflammation.

• A 2006 Nature paper on toxic oligomer Aβ*56 reinforced the hypothesis but was retracted in 2024 amid fraud allegations.

Amyloid Scandals In 2021, a neuroscientist identified doctored Western Blot images in Alzheimer's papers, including the 2006 Aβ56 study. Investigations revealed 20 papers by the lead author with manipulated images, 10 on Aβ56. A co-author withdrew collaboration suspecting misconduct. Skeptics noted inability to replicate Aβ*56 findings.

• NIH was notified in January 2022 but awarded the researcher a $764,792 grant in May 2022.

• Science exposed the fraud in July 2022; the paper was retracted in June 2024, with authors denying fault.

• In January 2025, RFK cited it during confirmation hearings; the researcher resigned February 2025.

The Amyloid Industry Amyloid drugs faced controversy: FDA approved Aduhelm despite 10-0 advisory panel rejection, leading to three resignations.

Priced at $56,000/year initially, later halved, Aduhelm caused brain swelling/bleeding in 41%.

Second drug (21% bleeding/swelling) slowed progression 26.4%

Third drug (36.8% bleeding/swelling) approved unanimously by new panel, despite conflicts in 9 out of 10 members per BMJ investigation.

• Drugs withdrawn or had low sales (e.g., first made $5 million total).

• Evidence suggests drugs damage brain tissue, indicating amyloid may protect brain or vessels.

• Coconut oil/Medium-chain triglycerides(MCT) stabilized/improved 80% in a trial over 6 months; 2022 study showed non-amyloid approaches reversed decline in 84% vs. 0% for amyloid drugs.

Dale Bredesen’s Discovery Dale Bredesen's model views amyloid as protective against stressors. Alzheimer's has subtypes needing targeted treatment.

Focus: identify type, remove causes, shift from neurodegeneration to neurodevelopment.

• 2018 report: 100 patients reversed decline.

• 2022 pilot: 84% improved cognition vs. 0% placebo.

• 2024: detailed case histories of remarkable responses.

• Improvements correlated with biochemical changes like reduced inflammation.

What Causes Alzheimer’s Disease? Bredesen identifies five subtypes:

• Type 1 – Inflammatory: From metabolic/infectious inflammation; presents with memory loss in 60s-70s.

• Type 1.5 – Glycotoxic: From insulin resistance/high sugar; common in prediabetes; late 50s-60s onset.

• Type 2 – Atrophic: Nutrient/hormone deficiencies (e.g., vitamin D, thyroid); emerges later than Type 1.

• Type 3 – Toxic: From biotoxins (e.g., mold, Lyme, metals); earlier onset (40s-60s); psychiatric symptoms.

• Type 4 – Vascular: Reduced blood flow (e.g., hypertension); affects speed/attention; 70s+ onset.

• Type 5 – Traumatic: From head injuries; common in athletes/veterans; impulsivity/emotional issues.

Notes: Alzheimer's is often called "type 3 diabetes." Misdiagnosis is common (12-63% error rates). Alzheimer’s overlaps with other dementias.

Zeta Potential and Alzheimer’s Zeta potential disperses particles in fluids; impairment causes agglomeration, impairing circulation/drainage. Decreases with age, linking to dementia.

• Poor zeta potential reduces glymphatic drainage (brain lymphatics), increasing toxic proteins.

• Aluminum may induce amyloid misfolding.

• Overlap with cardiovascular disease; physical inactivity links to 40-45% preventable dementia.

• Lymphatic-venous anastomosis (LVA) micro-surgery in China improves drainage, yielding dramatic short-term improvements.

Sleep and Dementia Poor sleep ties to dementia: studies show 71-139% higher risk with disorders such as insomnia.

• Disrupted sleep accelerates plaque accumulation; deep sleep mitigates impairment.

• Sleeping disorders 2-4.46 times more common in AD.

• Sleeping pills increase dementia risk 17-84%.

The Life of Cells Brain adapts by reinforcing/pruning circuits; Alzheimer's shifts balance to elimination.

• Amyloid precursor protein (APP) splits: two parts protect; four parts damage/eliminate cells.

• Exercise brain to prevent pruning.

Cell Danger Response Cells enter defensive state under stress, reducing function; seen in chronic illnesses.

• Integrated stress response (ISR) inhibitor restored memory/structure in mice.

• Senescent cells addressed by revival signals.

• Anesthesia may cause neurons to not wake, linking to decline; avoid inhaled types.

DMSO and Dementia DMSO protects cells, improves flow, reduces inflammation; treats strokes/injuries.

• Animal studies: prevented memory loss in rats; improved hippocampus in AD mice; delayed prion disease.

• Human studies: 18 AD patients improved memory/concentration over 9 months; 104 elderly improved with DMSO mixes; 100 cerebrovascular patients gained well-being/agility.

• Readers reported oral DMSO restored speech/personality in dementia cases.

Treating Dementia Prevent: mental activity, sunlight, sleep, exercise, metabolic health.

• DMSO: Topical (start 30-70%), oral (1 tsp in water), IV (3-5g diluted); protocols vary.

• Zeta Potential: Remove positive ions, deionized water, negative electrolytes; EDTA chelation (150-750mg); supplement Zn/Mg/Mn.

  ED NOTE 
  Zeta Aid is a supplement product that can help restore zeta potential: tinyurl.com/y82wwmae

• Head Trauma: Manual therapy (e.g., cranial sacral) for circulation/ drainage; liposomal melatonin; EECP.

• Other Therapies: Low-dose nicotine (2mg gum); IV amino acids; B1/B12 injections; lithium orotate.

• Cell Danger Response: Hooga lamp red light therapy (tinyurl.com/yc72cua3); UV blood irradiation; exosomes/stem cells.

Conclusion Systemic issues in Alzheimer's are part of chronic disease wave; profit-driven research has not solved the problem, while Bredesen's work and provider network are helping (apollohealthco.com).